Eli Lilly (LLY 0.55%) and Novo Nordisk (NVO 2.80%) benefit from innovative treatments for obesity and diabetes.
*Stock prices used were the afternoon prices of Jan. 5, 2025. The video was published on Jan. 7, 2025.
S&P 500
6,000.36
+1.0%
+$61.06
DJI
42,762.87
+1.0%
+$443.13
NASDAQ
19,529.95
+1.2%
+$231.50
Bitcoin
104,532.00
+2.6%
+2,635.28
AAPL
$204.23
+1.8%
+$3.60
AMZN
$213.68
+2.8%
+$5.77
GOOG
$174.93
+3.0%
+$5.12
META
$698.00
+2.0%
+$13.38
MSFT
$470.38
+0.6%
+$2.70
NVDA
$141.76
+1.3%
+$1.77
TSLA
$295.66
+3.8%
+$10.96
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
By Parkev Tatevosian, CFA
–
Jan 8, 2025 at 10:29AM
NYSE: LLY
Eli Lilly
Market Cap
$726B
Today's Change
(0.55%) $4.17
Current Price
$769.85
Price as of June 6, 2025, 3:58 p.m. ET
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
Stocks Mentioned
Eli Lilly
LLY
$769.85
(0.55%)
$4.17
Novo Nordisk
NVO
$74.69
(2.80%)
$2.04
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Should You Invest $1,000 in Eli Lilly today?
1 Underrated Reason to Buy This Market-Beating Stock
Prediction: Eli Lilly Will Reach a $1 Trillion Valuation by 2027
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.